Chairman of the Board of Directors of Tengion
President of Scheer & Company
David Scheer is President of Scheer & Company, Inc., a firm founded in 1981, with activities in venture capital, corporate strategy, and transactional advisory services focused on the life sciences. Mr. Scheer was involved in the founding and had been a member of the Boards of Directors of ViroPharma, Inc. (NASDAQ, “VPHM”), OraPharma, Inc. (acquired by Johnson & Johnson in 2003), and Esperion Therapeutics, Inc. (of which he was Chairman, acquired by Pfizer in 2004). His current board relationships include Achillion Pharmaceuticals, Inc. (of which he is Chairman, NASDAQ, “ACHN”), Tengion, Inc. (of which he is Chairman, NASDAQ, “TNGN”), Aegerion Pharmaceuticals, Inc. (of which he is Chairman), Optherion, Inc. (of which he is Chairman), and Axerion Therapeutics, Inc. (of which he is Chairman). From 1991 through 1999, he was affiliated with the health care investing team at Oak Investment Partners. Mr. Scheer has also led or played a significant role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. He has served as a member of the Leadership Council of the Harvard School of Public Health, and as a member of the Advisory Committee to the Harvard Malaria Initiative. He has helped to launch, and served as Chair of the Executive Committee for “The Unfinished Agenda in Infectious Diseases,” an initiative at the Harvard School of Public Health focusing on the neglected diseases. He has also been a member of the Global Advisory Council for AIDS@30, an initiative at Harvard, and the Chair of the Strategic Advisory Committee for the Global Task Force for Expanding Cancer Care and Control in the Developing World, another Harvard-affiliated initiative. He has also been a member of the Board of Trustees, and most recently Vice-Chair for the Long Wharf Theatre, in New Haven, CT. In 2007, he was awarded the Atlas Award for Venture Capital from the Connecticut Union for Research Excellence (CURE, of which he also serves as a member of the Board), and in 2009, he received the Venture Capital Leadership Award from the Connecticut Venture Group. He received his A.B. cum laude from Harvard College, and an M.S. from Yale University.
Carl-Johan Dalsgaard, M.D., Ph.D.
Partner, HealthCap Venture Capital
Dr. Dalsgaard serves as CEO of certain companies in which HealthCap has invested. He has been the start-up CEO of Biolipox AB, CePeP AB. Biofactor Therapeutics AB, and Biocrine AB. Prior to joining Odlander Fredrikson in 2000, Dr. Dalsgaard gained 10 years of senior management experience from the pharmaceutical industry as VP Preclinical Research, Astra Pain Control AB; President, Astra Pain Control AB and most recently VP and Head of Therapy Area Pain Control, AstraZeneca R&D. He became MD at the Karolinska Institute, has a Ph.D. in neurobiology, post-doc experience from Harvard Medical School, served as a tutor for Ph.D. students and published 79 scientific articles in the areas of neurobiology, cell biology and surgery. Dr. Dalsgaard has fulfilled specialist training for board certificate in plastic and reconstructive surgery at Karolinska Hospital.
Diane Jorkasky, M.D.
President, Diane K. Jorkasky, M.D., Consulting
Prior to her current role, Dr. Jorkasky was the enterprise-wide CMO of Endo Pharmaceuticals and a member of the senior R&D management team. Her responsibilities included chairing Endo's Safety Review Board, managing external partnerships and strategy development in the medical area, and ensuring the safety and ethical conduct of the company's clinical trials. Prior to joining Endo in 2011, she was Chief Development and Medical Officer at Aileron Therapeutics and previously held a variety of vice president level positions over nearly a decade with Pfizer Global R&D where she led global clinical research science and operational groups. She also currently sits on the Board of Directors of Q Therapeutics, Inc.
Dr. Jorkasky began her career at SmithKline Beecham, where she served as Vice President of Clinical Pharmacology for North America. She received her B.A. in Chemistry at the College of Wooster and her M.D. from the University of Pennsylvania and she is board-certified in nephrology, internal medicine and clinical pharmacology.
Richard E. Kuntz, M.D., M.Sc.
Senior Vice President and Chief Scientific, Clinical and Regulatory Officer, Medtronic, Inc.
Dr. Kuntz is Senior Vice President and Chief Scientific, Clinical and Regulatory Officer of Medtronic, Inc. In this role Dr. Kuntz oversees Medtronic's global regulatory affairs, health policy and reimbursement, clinical research activities, ventures and new therapies, strategy and innovation, corporate development, and acquisitions, integrations and divestitures functions. Dr. Kuntz brings a broad background and expertise in many different areas of healthcare. Prior to Medtronic he was the Founder and Chief Scientific Officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization which coordinates National Institutes of Health (NIH) and industry clinical trials with the United States Food and Drug Administration (FDA). Dr. Kuntz has directed over 100 multicenter clinical trials and has authored more than 200 original publications.
Dr. Kuntz also served as Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston, MA. Dr. Kuntz graduated from Miami University, and received his medical degree from Case Western Reserve University School of Medicine. He completed his residency in internal medicine at the University of Texas Southwestern Medical School, and then completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School, Boston. Dr. Kuntz received his master's of science in biostatistics from the Harvard School of Public Health.
John L. Miclot
President and CEO, Tengion, Inc.
Mr. Miclot brings nearly 25 years of healthcare industry experience and leadership to Tengion. Prior to leading CCS Medical, Mr. Miclot served as Chief Executive Officer of Philips Home Healthcare Solutions following the acquisition of Respironics, Inc. by Royal Philips. Mr. Miclot spent 10 years in senior roles at Respironics, ultimately serving as President and Chief Executive Officer from 2003 to 2008. While in that role, Mr. Miclot led Respironics to record annual revenues of more than $1 billion. Mr. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies, Inc., a medical device company. Mr. Miclot served in various positions at Healthdyne from 1995 to 1998, including Senior Vice President, Sales and Marketing. Earlier in his career, he held sales and marketing roles at Medex, Ohmeda, Baxter Edwards, and DeRoyal Industries. Mr. Miclot is a director of Wright Medical Group, Inc. and Dentsply International Inc., and serves as Chairman of the Board of Directors of Breathe Technologies, Inc. He is also a director of the Pittsburgh Zoo & PPG Aquarium and Burger King Cancer Caring Center. He earned his B.B.A. in marketing from the University of Iowa.
Lorin J. Randall
Mr. Randall, a financial consultant, brings more than 25 years experience to Tengion and most recently served as Interim CFO at Adnexus Therapeutics, Inc., a developer of oncology biologics which was acquired by Bristol-Myers Squibb in 2007. He has previously served as Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company and as Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices acquired by Abbott Laboratories in 2004. He currently serves on the Boards of Directors of Opexa Theraputics, Inc., Athersys, Inc., and Acorda Therapeutics, Inc. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.